Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Chronic Polyarticular Inflammatory CPPD
NCT07254637Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2026
- Primary completion
- Oct 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in calcium pyrophosphate deposition disease (CPPD), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
calcium pyrophosphate deposition disease (CPPD)
Beyond the preview
Go deeper on NCT07254637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254637.